Check Jerome H, Check Diane, Poretta Trina
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Cooper Medical School of Rowan University, Camden, NJ, U.S.A.
Cooper Institute for Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ, U.S.A.
Anticancer Res. 2019 Apr;39(4):1923-1926. doi: 10.21873/anticanres.13301.
Case 1 of an investigator-initiated study using oral single agent mifepristone to halt stage IV non-small cell lung cancer whose tumor was devoid of any targeted markers has remained ECOG zero and in good health for over 3 years. Case 2, reported here, is a 68-year-old woman with stage IV non-small cell lung cancer whose tumor was positive for the programmed death ligand-1 (PD-L1) marker. Her cancer progressed despite treatment with a check-point inhibitor (nivolumab), besides 3 rounds of multi-agent chemotherapy. After 1 ½ years of treatment with single agent mifepristone, her cancer remains stable (even some tumor regression) and her quality of life is only impaired by her pre-existing chronic obstructive lung disease, not her cancer.
Mifepristone therapy may provide a method to halt metastatic lung cancer positive for the PD-L1 marker when check-point inhibitors are no longer effective.
在一项研究者发起的研究中，使用口服单药米非司酮来治疗IV期非小细胞肺癌，该肿瘤没有任何靶向标志物，病例1的患者在超过3年的时间里保持了东部肿瘤协作组（ECOG）体能状态评分为0且健康状况良好。此处报告的病例2是一名68岁的IV期非小细胞肺癌女性患者，其肿瘤程序性死亡配体-1（PD-L1）标志物呈阳性。尽管接受了检查点抑制剂（纳武单抗）治疗以及3轮多药化疗，她的癌症仍进展。在接受单药米非司酮治疗1年半后，她的癌症保持稳定（甚至有一些肿瘤缩小），她的生活质量仅受到既往慢性阻塞性肺疾病的影响，而非癌症。
当检查点抑制剂不再有效时，米非司酮治疗可能为治疗PD-L1标志物呈阳性的转移性肺癌提供一种方法。
